BAYER AG

AI companies like Recursion Pharmaceuticals (RXRX) are disrupting biotech by reducing R&D costs, exemplified by RXRX's REC-1245 drug candidate for solid tumors and lymphoma, which reached FDA approval in under 18 months. RXRX plans to merge with Exscientia (EXAI) in 2025 and has partnerships with Bayer and Sanofi, with an average 12-month target price of $10.14 for RXRX stock.

E. Heath reports advisory/consulting, steering committee, honoraria/paid travel, speaker’s bureau, and research support from various companies. J.R. Ribeiro, K. Poorman, and J. Xiu report personal fees and other support from Caris Life Sciences. H. Mamdani reports other support and grants from Daiichi Sankyo, AstraZeneca, and Genentech. A.F. Shields reports personal fees from Caris Life Sciences. G.L. Lopes reports stock ownership, honoraria, consulting, research funding, travel, and other relationships with multiple companies. S.A. Kareff reports personal fees and travel grants from various organizations. M. Radovich and G.W. Sledge report other support from Caris Life Sciences. G.A. Vidal reports relationships with Guardant360, Gilead, BillionToOne, Genentech/Roche, GSK, and AstraZeneca. J.L. Marshall reports personal fees from Caris. No other disclosures were reported by the other authors.

The radiopharmaceuticals market was valued at USD 5.0 billion in 2023 and is projected to reach USD 16.6 billion by 2032, growing at a CAGR of 10.4%. The market is driven by increasing cancer cases and advancements in diagnostic and therapeutic radiopharmaceuticals. Technetium-99m dominates the market due to its wide diagnostic applications. North America holds the largest market share, while Asia Pacific is the fastest-growing region. Key players include GE Healthcare, Curium Pharma, and Lantheus.

Bristol Myers Squibb's Opdivo gains FDA approval for perioperative use in early-stage non-small cell lung cancer. Johnson & Johnson plans to invest $2 billion in a new biologics manufacturing facility in North Carolina. J&J, Bayer, and Bristol Myers Squibb are cutting jobs in New Jersey, while Pfizer plans to cut 210 jobs in Ireland. The WHO recommends RSV vaccination for pregnant women and antibody treatment for infants. Frazier Life Sciences raises $630 million for its evergreen Public Fund.

Pharmaceutical companies are conducting clinical trials in Brazil and Turkey due to lower costs. Regulatory reforms by TITCK and ANVISA streamline approval processes, attracting major firms like AstraZeneca and Merck. Phase 3 trials for cancer drugs like Aflibercept and Savolitinib are underway. Collaboration with local institutions and CROs enhances trial quality and efficiency, positioning these countries as key clinical research hubs.

A $110 million deal between Prime Medicine and Bristol Myers Squibb aims to develop next-gen T-cell therapies using Prime's PASSIGE technology. BlueRock Therapeutics reports positive 24-month data from its Phase I Parkinson's disease cell therapy trial, showing sustained benefits. Johnson & Johnson's CARVYKTI significantly extends survival in multiple myeloma patients, reducing the risk of death by 45% compared to standard therapies.

Yosi Health appoints Lori Ryan as Director of Customer Success and Patrick McInnis as VP of Partnerships. Precision for Medicine hires Margaret Keegan as CEO, succeeding Mark Clein as Executive Chairman. Cosmo Pharmaceuticals names Egle Gedrimaite Head of Global Business Development. Sumitomo Pharma America appoints Kenton Stewart as its first CCO. IGM elevates Mary Beth Harler to CEO. Pangea Biomed adds Dr. Kenneth D. Aldape to its scientific advisory board. Johnson & Johnson, Bayer, Pfizer, and CVS Health announce layoffs.

Kerendia, a nonsteroidal mineralocorticoid receptor antagonist, reduced cardiovascular death risk by 16% in HF patients with ejection fraction >40% in a phase 3 trial. Hyperkalemia incidence was higher but not significant, with no hospitalizations or deaths.

The global Transdermal Drug Delivery market is projected to grow from $80.6B in 2023 to $235.3B by 2030, driven by chronic disease prevalence, technological advancements, and non-invasive delivery benefits. The report provides insights on market trends, regional analysis, and key players.

Dr. Robb Fraley, former Monsanto CTO, pioneered biotechnology in agriculture, leading to innovations like Roundup Ready crops. His work significantly impacted global food security, earning him prestigious awards. Fraley emphasizes the ongoing potential of biotechnology and gene-editing in agriculture.